MGNREGA is certainly a good idea. But it can’t be allowed to play havoc with farming operations by weaning away labourers during peak season RURAL DEVELOPMENT Minister Jairam Ramesh recently rubbished the need for freezing the flagship rural job scheme MGNREGA during peak agricultural season. Dismissing the possibility, Ramesh had said: “The matter has been examined by the Mihir Shah Committee and rejected.” Knowing that Mihir Shah’s entry into Planning Commission...

India, like other Asian countries, has focused its climate change adaptation strategies on rural and urban areas while neglecting the urban fringes, say experts. Peri-urban areas are characterised by haphazard, accelerated expansion and are farthest from basic urban services and infrastructure, according to United Nations-Habitat’s ‘The State of Asian Cities 2010-11’. By 2020, of the projected 4.2 billion urban population of the world, 2.2 billion will be living in Asia, many...

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...

In a landmark decision, India’s intellectual property office on Monday allowed Hyderabad-based Natco Pharma Ltd to make and sell a copycat version of German drug maker Bayer AG’s patented cancer treatment Nexavar. It’s the first time that an Indian company has been granted the so-called compulsory licence to market a generic version of a patented drug. The drug, patented by Bayer in India in 2008, is used in the treatment of...

In a landmark decision that could set a precedent on how life-saving drugs under patents can be made affordable, the government has allowed a domestic company, Natco Pharma, to manufacture a copycat version of Bayer's patented anti-cancer drug, Nexavar, bringing down its price by 97%. In the first-ever case of compulsory licencing approval, the Indian Patent Office on Monday cleared the application of Hyderabad's Natco Pharma to sell generic drug Nexavar,...